All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke with Giovanna Lucchini, Great Ormond Street Hospital, London, UK. We asked, How does graft-versus-host disease (GvHD) affect outcomes for pediatric patients undergoing allogeneic stem cell transplantation (allo-SCT) for acute lymphoblastic leukemia (ALL)?

How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?

Lucchini begins by describing how background disorders impact GvHD in patients post transplant. Lucchini then discusses the concept of engineering GvHD that is 'enough, but not too much' and highlights the need for more strategies to support patients and control GvHD.